Literature DB >> 21931031

Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.

Susan M Domchek1, Gillian Mitchell, Geoffrey J Lindeman, Nadine M Tung, Judith Balmaña, Steven J Isakoff, Rita Schmutzler, M William Audeh, Niklas Loman, Clare Scott, Michael Friedlander, Bella Kaufman, Judy E Garber, Andrew Tutt, Mark E Robson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21931031     DOI： 10.1200/JCO.2011.36.8134

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Cancer treatment according to BRCA1 and BRCA2 mutations.

Authors:  Kara N Maxwell; Susan M Domchek
Journal:  Nat Rev Clin Oncol       Date:  2012-07-24       Impact factor: 66.675

Review 2.  Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

Authors:  Clare L Scott; Elizabeth M Swisher; Scott H Kaufmann
Journal:  J Clin Oncol       Date:  2015-03-16       Impact factor: 44.544

3.  Systemic treatment for hereditary cancers: a 2012 update.

Authors:  Evgeny N Imyanitov; Tomasz Byrski
Journal:  Hered Cancer Clin Pract       Date:  2013-04-01       Impact factor: 2.857

Review 4.  Advances in using PARP inhibitors to treat cancer.

Authors:  Shivaani Kummar; Alice Chen; Ralph E Parchment; Robert J Kinders; Jay Ji; Joseph E Tomaszewski; James H Doroshow
Journal:  BMC Med       Date:  2012-03-09       Impact factor: 8.775

5.  Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.

Authors:  Richard T Penson; Ricardo Villalobos Valencia; David Cibula; Nicoletta Colombo; Charles A Leath; Mariusz Bidziński; Jae-Weon Kim; Joo Hyun Nam; Radoslaw Madry; Carlos Hernández; Paulo A R Mora; Sang Young Ryu; Tsveta Milenkova; Elizabeth S Lowe; Laura Barker; Giovanni Scambia
Journal:  J Clin Oncol       Date:  2020-02-19       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.